IL17A and COVID-19: Noteworthy, the treatment of COVID-19 using IL-17 inhibitor such as Secukinumab (human monoclonal antibody to IL-17) did not improve patients’ hospitalization time and intensive care unit demand (Resende et al., 2022), possibly because IL-17R can also be hijacked by SARS-CoV-2 ORF8 protein, which interacts with IL-17RA and activates the pathway in a stronger and broader manner than IL-17 (Lin et al., 2021; Wu et al., 2022).